References on the Administration of Antisense Oligonucleotides Using ALZET^® Osmotic Pumps

Q0912 Qian,N.S., Liao,Y.H., Feng,Q.X., Tang,Y., Dou,K.F., Tao,K.S. Spinal toll like receptor 3 is involved in chronic pancreatitis-induced mechanical allodynia of rat. Molecular Pain 2011; 7(-;-):U1-U11. >>> Oligodeoxynucleotide, antisense; oligodeoxynucleotide, mismatch; CSF/CNS (intrathecal); Rat; 2001; 1 week; Negative cntrols received mp w/ mismatch oligodeoxynucleotide; animal info (male, Sprague-Dawley, 250-300 g, laminectomy); antisense (TLR3); PE-10 catheter used.

Q0114 Elazar,V., Adwan,H., Baeuerle,T., Rohekar,K., Golomb,G., Berger,M.R. Sustained delivery and efficacy of polymeric nanoparticles containing osteopontin and bone sialoprotein antisenses in rats with breast cancer bone metastasis. International Journal of Cancer 2010; 126(-7-):1749-1760. >>> Oligonucleotide, phosphorothioate antisense; oligonucleotide, phosphorothioate missense; PBS; SC; Rat (nude); 4 weeks; Controls received mp w/ nonsense oligo; antisense (osteopontin, bone sialoprotein); cancer (breast); animal info (RNU nude, 6-8 weeks old); comparison of polymeric nanoparticles vs mp; pumps replaced after 2 weeks.

Q0115 Garcia-Galiano,D., Navarro,V.M., Roa,J., Ruiz-Pino,F., Sanchez-Garrido,M.A., Pineda,R., Castellano,J.M., Romero,M., Aguilar,E., Gaytan,F., Dieguez,C., Pinilla,L., Tena-Sempere,M. The Anorexigenic Neuropeptide, Nesfatin-1, Is Indispensable for Normal Puberty Onset in the Female Rat. Journal of Neuroscience 2010; 30(-23-):7783-7792. >>> Oligonucleotide, antisense, morpholino; oligonucleotide, missense, morpholino; Saline; CSF/CNS; Rat; 2001; 7 days; Controls received mp w/ missense oligo; antisense (Nucleobindin 2); animal info (female, Wistar, 28 days old, adult); endocrinology.

Q0494 Ibi,D., Nitta,A., Ishige,K., Cen,X.B., Ohtakara,T., Nabeshima,T., Ito,Y. Piccolo knockdown-induced impairments of spatial learning and long-term potentiation in the hippocampal CA1 region. NEUROCHEMISTRY INTERNATIONAL 2010; 56(-1-):77-83. >>> Oligonucleotide, antisense; CSF/CNS; Mice; 1002; 7 days; Controls received mp w/ sense; antisense (piccolo); ALZET brain infusion kit 3 used; animal info (male, C57BL/6J, 8-10 wks old).

Q0178 Obata,K., Katsura,H., Mizushima,T., Yamanaka,H., Kobayashi,K., Dai,Y., Fukuoka,T., Tokunaga,A., Tominaga,M., Noguchi,K. TRPA1 induced in sensory neurons contributes to cold hyperalgesia after inflammation and nerve injury (vol 115, pg 2393, 2005). Journal of Clinical Investigation 2010; 120(-1-):394-394. >>> SB203580; antibody, anti-NGF; oligodeoxynucleotide, antisense; oligodeoxynucleotide, missense; oligodeoxynucleotide, FITC-, antisense; Saline; DMSO; CSF/CNS (intrathecal); Rat; 2001; 7 days; Controls received mp w/ missense oligo; animal info (male, Sprague-Dawley, 200-250 g, SNL); antisense (TRPA1); enzyme inhibitor (p38 MAP kinase); 50% DMSO; behavioral testing (basal pain hypersensitivity, paw withdrawal latency, mechanical withdrawal threshold).

Q0086 Silvestre,D.C., Gil,G.A., Tomasini,N., Bussolino,D.F., Caputto,B.L. Growth of Peripheral and Central Nervous System Tumors Is Supported by Cytoplasmic c-Fos in Humans and Mice. PLoS One 2010; 5(-3-):U234-U243. >>> Oligonucleotide, antisense; oligonucleotide, scrambled; CSF/CNS (caudate putamen); Mice; 2004; 28 days; Controls received mp w/ vehicle; antisense (C-Fos mRNA morpholino); animal info (4 months old, NPcis).

Q0497 Yin,K.J., Deng,Z., Huang,H.R., Hamblin,M., Xie,C.Q., Zhang,J.F., Chen,Y.E. miR-497 regulates neuronal death in mouse brain after transient focal cerebral ischemia. NEUROBIOLOGY OF DISEASE 2010; 38(-1-):17-26. >>> Oligonucleotide, antisense; CSF, artificial; CSF/CNS; Mice; 1003D; ; Negative controls received mp w/ miR-antagomir negative control or artificial CSF; antisense (miR-497); animal info (male, C57/Bl6); ischemia (focal cerebral).

Q0438 Chan,S.H.H., Wu,C.A., Wu,K.L.H., Ho,Y.H., Chang,A.Y.W., Chan,J.Y.H. Transcriptional Upregulation of Mitochondrial Uncoupling Protein 2 Protects Against Oxidative Stress-Associated Neurogenic Hypertension. Circulation Research 2009; 105(-9-):886-U145. >>> Rosiglitazone; oligonucleotide, antisense; angiotensin II; CSF, artificial; DMSO; CSF/CNS; CSF/CNS (intrathecal, cisterna magna); 2001; 7 days; Controls received mp w/ vehicle; animal info (adult, male Sprague-Dawley, 10-11 wks old); antisense (UCP2); peptides; 0.5% DMSO used.

P9755 Cheng,L.C., Pastrana,E., Tavazoie,M., Doetsch,F. miR-124 regulates adult neurogenesis in the subventricular zone stem cell niche. Nature Neuroscience 2009; 12(-4-):399-408. >>> Oligonucleotide, antisense; Ara-C; Saline; CSF/CNS; Mice; 1007D; 12, 14 days; Pumps replaced after 6 days; antisense (miR-124); animal info (2 months old, CD-1); brain tissue distribution.

P9481 Geary,R.S., Wancewicz,E., Matson,J., Pearce,M., Siwkowski,A., Swayze,E., Bennett,F. Effect of dose and plasma concentration on liver uptake and pharmacologic activity of a 2'-methoxyethyl modified chimeric antisense oligonucleotide targeting PTEN. Biochemical Pharmacology 2009; 78(-3-):284-291. >>> Oligonucleotide, antisense; oligonucleotide, nonsense; Saline; SC; Mice; 24, 72, 168 hours; Controls received mp w/ vehicle; dose-response (fig 3, 4); comparison of SC injections vs. mp; animal info (Balb/C, male, 20-25 g.); antisense (ISIS 1 16847); nonsense (ISIS 13920).

P9824 Gerzanich,V., Woo,S.K., Vennekens,R., Tsymbalyuk,O., Ivanova,S., Ivanov,A., Geng,Z.H., Chen,Z., Nilius,B., Flockerzi,V., Freichel,M., Simard,J.M. De novo expression of Trpm4 initiates secondary hemorrhage in spinal cord injury. Nature Medicine 2009; 15(-2-):185-191. >>> Oligonucleotide, antisense; IV (jugular); Rat; 24 hours; Controls received mp w/ sense; antisense (Trpm4); animal info (adult, female, Long Evans, 275-350 g); SCI; spinal cord injury.

P9865 Kocerha,J., Faghihi,M.A., Lopez-Toledano,M.A., Huang,J., Ramsey,A.J., Caron,M.G., Sales,N., Willoughby,D., Elmen,J., Hansen,H.F., Orum,H., Kauppinen,S., Kenny,P.J., Wahlestedt,C. MicroRNA-219 modulates NMDA receptor-mediated neurobehavioral dysfunction. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 2009; 106(-9-):3507-3512. >>> MK-801; oligonucleotide, antisense; SC; CSF/CNS; Mice; 1002; 2002; 5, 7 days; Controls received mp w/ saline; antisense (LNA-antimiR-219); animal info (12 wks old, 25 g.); tygon tubing used; MK-801 also known as dizocilpine.

Q0270 Kondo,T., Obata,K., Miyoshi,K., Sakurai,J., Tanaka,J., Miwa,H., Noguchi,K. Transient receptor potential A1 mediates gastric distention-induced visceral pain in rats. Gut 2009; 58(-10-):1342-1352. >>> Oligodeoxynucleotide, antisense; oligodeoxynucleotide, mismatch; Saline, normal; CSF/CNS (intrathecal); Rat; 1003D; ; Controls received mp w/ vehicle; animal info (male, Sprague-Dawley, 190-260 g.); antisense (TRPA1); incorrectly listed Model 2003 pumps.

Q0065 Simard,J.M., Kilbourne,M., Tsymbalyuk,O., Tosun,C., Caridi,J., Ivanova,S., Keledjian,K., Bochicchio,G., Gerzanich,V. Key Role of Sulfonylurea Receptor 1 in Progressive Secondary Hemorrhage after Brain Contusion. Journal of Neurotrauma 2009; 26(-12-):2257-2267. >>> Glibenclamide; oligodeoxynucleotide, antisense; DMSC; saline, unbuffered; Rat; 2001D; 2001; 7 days; 24 hours; Controls received mp w/ scrambled oligos; antisense (Abcc8); animal info (male, Long Evans 275-300 g.).

Q0517 Wang,X., Chow,F.L., Oka,T., Hao,L., Lopez-Campistrous,A., Kelly,S., Cooper,S., Odenbach,J., Finegan,B.A., Schulz,R., Kassiri,Z., Lopaschuk,G.D., Fernandez-Patron,C. Matrix Metalloproteinase-7 and ADAM-12 (a Disintegrin and Metalloproteinase-12) Define a Signaling Axis in Agonist-Induced Hypertension and Cardiac Hypertrophy. Circulation 2009; 119(-18-):2480-U112. >>> Oligonucleotide, antisense; oligonucleotide, scrambled; RNA, small interferring; angiotensin II; PBS; SC; Mice; rat; 14 days; Controls received mp w/ vehicle; animal info (MMP-7-/-, wt, 12 wks old; SHR, WKY, Sprague Dawley, 250-350 g); peptides; antisense (MMP-7); multiple pumps per animal (2); blood pressure measured indirectly using a computerized tail cuff plethysmography system.

P9659 Wilson-Gerwing,T.D., Johnston,J.M., Verge,V.M.K. p75 Neurotrophin Receptor Is Implicated in the Ability of Neurotrophin-3 to Negatively Modulate Activated ERK1/2 Signaling in TrkA-Expressing Adult Sensory Neurons. Journal of Comparative Neurology 2009; 516(-1-):49-58. >>> Neurotrophin 3; oligonucleotides, antisense; oligonucleotides, sense; PBS; Streptomycin; albumin, rat serum; penicillin; CSF/CNS (intrathecal); Rat; 2001; 7 days; Controls received mp w/vehicle; functionality of mp verified by flurorescence; antisense (P75); animal info (young male, wistar, 250-300.

Q0625 Yoon,H., Kim,D.J., Ahn,E.H., Gellert,G.C., Shay,J.W., Ahn,C.H., Lee,Y.B. Antitumor Activity of a Novel Antisense Oligonucleotide Against Akt1. Journal of Cellular Biochemistry 2009; 108(-4-):832-838. >>> Oligonucleotide, antisense; IP; Mice (nude); 1002; 14 days; Animal info (nu/nu); bioluminescence.

P9392 Bosch,O.J., Neumann,I.D. Brain vasopressin is an important regulator of maternal behavior independent of dams' trait anxiety. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 2008; 105(-44-):17139-17144. >>> Vasopressin, arginine; oxytocin; oligonucleotide, antisense; oligonucleotide, missense; Ringer's solution; CSF/CNS; CSF/CNS (medial preoptic area); Rat (pregnant); 1007D; 5-7 days; Controls received mp w/ vehicle; comparison of ICV injections vs. mp; antisense (AVP-R); peptides; multiple pumps per animal (2); post op. care (Enrofloxacin, Baytril); animal info (female, Wistar, HAB, LAB, 14 wks old); behavioral testing (maternal care, pup retrieval test, elevated plus maze); cannula placement and infusion sites verified with blue ink.

P8846 Dikmen,Z.G., Gellert,G.C., Dogan,P., Yoon,H., Lee,Y.B., Ahn,C.H., Shay,J.W. In vivo and in vitro effects of a HIF-1alpha inhibitor, RX-0047. Journal of Cellular Biochemistry 2008; 104(-3-):985-994. >>> RX-0047; oligonucleotide, phosphorothioate antisense; SC; IP; Mice (nude); 1002; 14 days; Controls received no treatment; comparison of IP injections vs. mp; antisense (HIF-1a); cancer (lung, prostate); animal info (Nu/Nu).

P8437 Henke,E., Perk,J., Vider,J., de Candia,P., Chin,Y., Solit,D.B., Ponomarev,V., Cartegni,L., Manova,K., Rosen,N., Benezra,R. Peptide-conjugated antisense oligonucleotides for targeted inhibition of a transcriptional regulator in vivo. NATURE BIOTECHNOLOGY 2008; 26(-1-):91-100. >>> Oligonucleotide, antisense, peptide conjugated; oligonucleotide, phosphorothioate antisense; peptide, F3; TBS; SC; Mice (nude); mice; 1007D; 1002; 14, 21 days; Controls received mp w/ vehicle or control peptide and oligo in non-conjugated form, or rcId1-PCAO; comparison of IV injections vs. mp; pumps replaced after 14 days; no stress (see pg. 95, 97); stability verified after 24 hours in 37 C, plasma up to 28 days in 37 C saline; antisense (Id1, rcId1); cancer (breast, lung carcinoma); peptides; toxicology; animal info (female, nude NCR; male, C57J/B6); antisense oligos covalently coupled to address peptide that targets tumor endothelial cells; "no adverse effects on treated mice have been observed." (p. 97).

P9486 Johnson,M.A., Fraley,G.S. Rat RFRP-3 Alters Hypothalamic GHRH Expression and Growth Hormone Secretion but Does Not Affect KiSS-1 Gene Expression or the Onset of Puberty in Male Rats. Neuroendocrinology 2008; 88(-4-):305-315. >>> Oligonucleotide, antisense; oligonucleotide, mismatch; NPFF; RFamide-related peptide-3; PBS; CSF/CNS; CSF/CNS (third ventricle); Rat; 2002; 7, 14 days; Controls received mp w/ vehicle or mismatch ODN; functionality of mp verified; antisense (RFRP-3); ALZET brain infusion kit used; peptides; animal info (male, Sprague Dawley, 24 days old, 60 g., 35 days old); endocrinology; cannula placement confirmed histologically at end of experiment.

P9331 Kim,D.H., Fitzsimmons,B., Hefferan,M.P., Svensson,C.I., Wancewicz,E., Monia,B.P., Hung,G., Butler,M., Marsala,M., Hua,X.Y., Yaksh,T.L. Inhibition of spinal cytosolic phospholipase A2 expression by an antisense oligonucleotide attenuates tissue injury-induced hyperalgesia. Neuroscience 2008; 154(-3-):1077-1087. >>> Oligonucleotide, phosphorothioate antisense; oligonucleotide, phosphorothioate missense; Saline; CSF/CNS (intrathecal); Rat; 2001; 5 days; Controls received mp w/ missense oligo; dose-response (fig. 2); antisense (cPLA2IVA); animal info (male, Holzmann, 300-350 g.); agents specifically known as ISIS 122523 and ISIS 141923; behavioral testing (thermal paw withdrawal test, formalin-induced flinching).

P9240 Niwa,M., Nitta,A., Cen,X., Kitaichi,K., Ozaki,N., Yamada,K., Nabeshima,T. A novel molecule 'shati' increases dopamine uptake via the induction of tumor necrosis factor-alpha in pheochromocytoma-12 cells. Journal of Neurochemistry 2008; 107(-6-):1697-1708. >>> Oligonucleotide, antisense phosphorothioate; oligonucleotide, missense phosphorothioate; CSF, artificial; CSF/CNS; Mice; 1002; 8 days; Controls received mp w/ vehicle or missense oligo; antisense (Shati); animal info (male, C57BL/6J); aCSF recipe.

P9441 Sakai,A., Asada,M., Seno,N., Suzuki,H. Involvement of neural cell adhesion molecule signaling in glial cell line-derived neurotrophic factor-induced analgesia in a rat model of neuropathic pain. Pain 2008; 137(-2-):378-388. >>> Oligodeoxynucleotide, phosphorothioate antisense; glial-derived neurotrophic factor, recomb. human; neural cell adhesion molecule, mimetic peptide C3d; oligodeoxynucleotide, phosphorothioate missense; CSF/CNS (subarachnoid space); Rat; 4, 6, 7, 9 days; Controls received mp w/ saline; antisense (NCAM); peptides; multiple pumps per animal (2); animal info (male, Sprague Dawley, 5 wks old, 140-160 g., sciatic nerve injury); behavioral testing (mechanical allodynia, thermal hypersensitivity, paw withdrawal, plantar test).

P9468 Yang,J., Li,Y.Q., Zuo,X.L., Zhen,Y.B., Yu,Y.B., Gao,L.J. Transient receptor potential ankyrin-1 participates in visceral hyperalgesia following experimental colitis. Neuroscience Letters 2008; 440(-3-):237-241. >>> Oligodeoxynucleotide, antisense; oligodeoxynucleotide, missense; Saline, nuclease-free; CSF/CNS (intrathecal); Rat; 2001; 3 days; Controls received mp w/ vehicle; antisense (TRPA1); animal info (male, Wistar, 250-300 g.).

P9687 Yatabe,J., Sanada,H., Midorikawa,S., Hashimoto,S., Watanabe,T., Andrews,P.M., Armando,I., Wang,X.Y., Felder,R.A., Jose,P.A. Effects of Decreased Renal Cortical Expression of G Protein-Coupled Receptor Kinase 4 and Angiotensin Type 1 Receptors in Rats. HYPERTENSION RESEARCH 2008; 31(-7-):1455-1464. >>> Oligodeoxynucleotide, antisense; oligodeoxynucleotide, scrambled; G-protein-coupled receptor kinase 4; Ringer's solution, lactated; Kidney; Rat; 5 weeks; Controls received mp w/ vehicle; pumps replaced following 1 week recovery period; antisense (GRK4, AT1R); animal info (4 wks old, male, WKY, SHR, uninephrectomized); tissue perfusion (kidney).

P9084 Zhang,J.J., Zafrullah,M., Yang,X., Yin,X.L., Zhang,Z.G., Fuks,Z., Kolesnick,R. Downregulation of KSR1 in pancreatic cancer xenografts by antisense oligonucleotide correlates with tumor drug uptake. CANCER BIOLOGY&THERAPY 2008; 7(-9-):1492-1497. >>> Oligonucleotide, antisense; PBS; SC; Mice; 5 days; Controls received mp w/ vehicle; antisense (KSR1); cancer (pancreatic).

Q0050 Care,A., Catalucci,D., Felicetti,F., Bonci,D., Addario,A., Gallo,P., Bang,M.L., Segnalini,P., Gu,Y.S., Dalton,N.D., Elia,L., Latronico,M.V.G., Hoydal,M., Autore,C., Russo,M.A., Dorn,GW II, Ellingsen,O., Ruiz-Lozano,P., Peterson,K.L., Croce,C.M., Peschle,C., Condorelli,G. MicroRNA-133 controls cardiac hypertrophy. Nature Medicine 2007; 13(-5-):613-618. >>> Oligonucleotide, antisense RNA; SC; Mice; 1003D; ; Controls received mp w/ saline; cardiovascular; antisense (miR-133); animal info (female, C57BL/6, 8 weeks old); agent also referred to as "antagomir".

P8400 Mizushima,T., Obata,K., Katsura,H., Sakurai,J., Kobayashi,K., Yamanaka,H., Dai,Y., Fukuoka,T., Mashimo,T., Noguchi,K. Intensity-dependent activation of extracellular signal-regulated protein kinase 5 in sensory neurons contributes to pain hypersensitivity. Journal of Pharmacology and Experimental Therapeutics 2007; 321(-1-):28-34. >>> Oligodeoxynucleotide, phosphorothioate antisense; oligodeoxynucleotide, phosphorothioate missense; oligodeoxynucleotide, FITC-labeled; Saline; CSF/CNS (intrathecal, subarachnoid space); Rat; 1003D; 3 days; Controls received mp w/ vehicle; dose-response (fig. 5); antisense (ERK5); brain tissue distribution; animal info (male, Sprague-Dawley, 220-250g.).

P8532 Moenkkoenen,K.S., Hakumaeki,J.M., Hirst,R.A., Miettinen,R.A., O'Callaghan,C., Maennistoe,P.T., Laitinen,J.T. Intracerebroventricular antisense knockdown of G alpha i2 results in ciliary stasis and ventricular dilatation in the rat. BMC NEUROSCIENCE 2007; 8(--):U12-U26. >>> Oligodeoxynucleotide, antisense; oligodeoxynucleotide, missense; Saline, sterile; CSF/CNS; Rat; 1007D; 2002; 7,11 days; Controls received mp w/ vehicle or nonsense or mismatched oligos; no stress (see pg. 2); antisense (G alpha i2); brain tissue distribution; animal info (male, Harlan Wistar, 3 weeks old, 50-100 grams, adult, 250 grams).

P9104 Monkkonen,K.S., Hakumaki,J.M., Hirst,R.A., Miettinen,R.A., O'Callaghan,C., Mannisto,P.T., Laitinen,J.T. Intracerebroventricular antisense knockdown of G alphai2 results in ciliary stasis and ventricular dilatation in the rat. BMC.Neurosci. 2007; 8(--):26-. >>> Oligodeoxynucleotide, antisense; oligodeoxynucleotide, nonsense; oligodeoxynucleotide, mismatch; Saline, sterile; CSF/CNS; Rat; 1007D; 2002; 7 days; Controls received mp w/ vehicle; no stress (see pg. 2 of 15); MRI; animal info (male, Harlan Wistar, 3-5 wks old, 50-100 g.; adult, 250 g.).

P8850 Nakayama,H., Kitaichi,K., Ito,Y., Hashimotoa,K., Takagi,K., Yokoi,T., Takagi,K., Ozaki,N., Yamamoto,T., Hasegawa,T. The role of organic cation transporter-3 in methamphetamine disposition and its behavioral response in rats. Brain Research 2007; 1184(-;-):260-269. >>> Oligodeoxynucleotide, phosphorothioate antisense; oligodeoxynucleotide, phosphorothioate missense; Ringer's solution; CSF/CNS; Rat; 1003D; 3 days; Controls received mp w/ missense ODN; no stress (see pg. 266); antisense (OCT3); ALZET brain infusion kit used; animal info (male, Wistar, 280-300g.); "The dose and infusion period of OCT3-AS and OCT-SCR did not produce any abnormal behavior or weight loss." (p. 266).

P8665 Reading,S.A., Brayden,J.E. Central role of TRPM4 channels in cerebral blood flow regulation. Stroke 2007; 38(-8-):2322-2328. >>> Oligonucleotide, phosphorothioate sense; oligonucleotide, phosphorothioate antisense; CSF, artificial; CSF/CNS; Rat; 2001; 7 days; Controls received mp w/ ODN, sense; antisense (TRPM4); ALZET braininfusion kit 1 used; animal info (male, Sprague-Dawley, 400-550g; "Efficient uptake of oligonucleotides by vascular myocytes in vivo may have resulted from the long exposure time during which the osmotic pumps continuously refresh the ODNs in the CSF over many days" (p. 2326).

P8643 Simard,J.M., Tsymbalyuk,O., Ivanov,A., Ivanova,S., Bhatta,S., Geng,Z.H., Woo,S.K., Gerzanich,V. Endothelial sulfonylurea receptor 1- regulated NCCa-ATP channels mediate progressive hemorrhagic necrosis following spinal cord injury. Journal of Clinical Investigation 2007; 117(-8-):2105-2113. >>> Glibenclamide; oligodeoxynucleotide, phosphorothioate missense; repaglinide; oligodeoxynucleotide, antisense; oligodeoxynucleotide, phosphorothioate antisense; oligodeoxynucleotide, missense; Saline; PBS; DMSO; SC; IV (jugular); CSF/CNS (parietal lobe); Rat; 2002; 1, 7, 10-14 days; Controls received mp w/ vehicle; antisense (Abcc8); ischemia (cerebral); animal info (female, Long-Evans, 275-350g, acute SCI); "We used constant infusion of a low dose of drug to achieve sustained occupancy of only high-affinity receptors." (p. 2109).

P8505 Yurovsky,V.V., Gerzanich,V., Ivanova,S., Dong,Y., Tsymbalyuk,O., Simard,J.M. Autocrine TGF-beta1 mediates angiotensin II-Induced proliferative response of cerebral vessels in vivo. American Journal of Hypertension 2007; 20(-9-):950-956. >>> Angiotensin II; oligodeoxynucleotide, antisense; Saline; SC; CSF/CNS (intrathecal, cisterna magna); Rat; 2001; 2004; 4-28 days; Controls received mp w/ vehicle; blood pressure taken; antisense (TGF, beta); cardiovascular; peptides; second pump placed IT to deliver ODN.

P8134 Figueroa,J.D., Benton,R.L., Velazquez,I., Torrado,A.I., Ortiz,C.M., Hernandez,C.M., Diaz,J.J., Magnuson,D.S., Whittemore,S.R., Miranda,J.D. Inhibition of EphA7 up-regulation after spinal cord injury reduces apoptosis and promotes locomotor recovery. Journal of Neuroscience Research 2006; 84(-7-):1438-1451. >>> Oligonucleotide, missense; oligonucleotide, antisense; oligonucleotide, FITC antisense; CSF/CNS (intrathecal); Rat; 2002; 1, 2, 3, 4 weeks; Controls received mp w/ missense oligonucleotide; antinsense (EphA7); brain tissue distribution; cyanoacrylate adhesive; animal info (female, Sprague-Dawley, 200-275g., SCI contusion); mp primed overnight in 37 celsius.

P7817 Igwe,O.J. Agents that act by different mechanisms modulate the activity of protein kinase C beta II isozyme in the rat spinal cord during peripheral inflammation. Neuroscience 2006; 138(-1-):313-328. >>> L-703606 oxalate; dextrorphan tartrate; oligodeoxynucleotide, phosporothioate antisense; phosporothioate missense; Propylene glycol; water, sterile; saline; oligofectamine; SC; Rat; 2001; 7 days; Controls received mp w/ vehicle; dose-response (fig 1); stability verified; antisense (protein kinase C, beta); animal info (male, Sprague-Dawley, 200-300 grams); "mini osmotic pumps were used to administer all agents in order to reduce animal handling after CFA-induced inflammation." (p. 315).

P8113 Kanehisa,M., Akiyoshi,J., Kitaichi,T., Matsushita,H., Tanaka,E., Kodama,K., Hanada,H., Isogawa,K. Administration of antisense DNA for ghrelin causes an antidepressant and anxiolytic response in rats. PROGRESS IN NEURO-PSYCHOPHARMACOLOGY&BIOLOGICAL PSYCHIATRY 2006; 30(-8-):1403-1407. >>> Oligodeoxynucleotide, antisense; oligodeoxynucleotide, missense; Saline; CSF/CNS; Rat; 1003D; 1007D; 3 days; Controls received mp w/ vehicle, or missense oligo; antisense (ghrelin); post op. care (ceftriaxone sodium); animal info (male, Wistar, 7-9 wks old, 300-330g.).

P8969 Katsura,H., Obata,K., Mizushima,T., Yamanaka,H., Kobayashi,K., Dai,Y., Fukuoka,T., Tokunaga,A., Sakagami,M., Noguchi,K. Antisense knock down of TRPA1, but not TRPM8. alleviates cold hyperalgesia after spinal nerve ligation in rats. Experimental Neurology 2006; 200(-1-):112-123. >>> Oligodeoxynucleotide, antisense; oligodeoxynucleotide, mismatch; Saline, normal; CSF/CNS (intrathecal); Rat; 2001; 3, 5, 7days; 6, 12, 24 hours; Controls received mp w/ vehicle; antisense (TRPA1, TRPM8); animal info (male, Sprague Dawley, SNL, 200-250 g.).

P8408 Proudfoot,C.J., Garry,E.M., Cottrell,D.F., Rosie,R., Anderson,H., Robertson,D.C., Fleetwood-Walker,S.M., Mitchel,R. Analgesia mediated by the TRPM8 cold receptor in chronic neuropathic pain. CURRENT BIOLOGY 2006; 16(-16-):1591-1605. >>> Oligonucleotide, phosphorothioate antisense; Oligonucleotide, phosphorothioate missense; Saline, sterile; CSF/CNS (intrathecal); Rat; 2001; 2002; 5, 13-16 days; Controls received mp w/ missense oligo; antisense (TRPM8, rat); animal info (male, Wistar, 120-250g., chronic constriction sciatic nerve injury).

P8320 Rygh,L.J., Suzuki,R., Rahman,W., Wong,Y., Vonsy,J.L., Sandhu,H., Webber,M., Hunt,S., Dickenson,A.H. Local and descending circuits regulate long-term potentiation and zif268 expression in spinal neurons. European Journal of Neuroscience 2006; 24(-3-):761-772. >>> Oligodeoxynucleotide, phosphorothioate antisense; oligodeoxynucleotide, phosphorothioate, mismatch; Saline; CSF/CNS (intrathecal); Rat; 2001; 7 days; Controls received mp w/ vehicle or mismatch ODN or no treatment; antisense (zif268); animal info (male, Sprague-Dawley, 130-150 grams); dye injections used to confirm cannula placement.

P7849 Sanada,H., Yatabe,J., Midorikawa,S., Katoh,T., Hashimoto,S., Watanabe,T., Xu,J., Luo,Y.J., Wang,X.Y., Zeng,C.Y., Armando,I., Felder,R.A., Jose,P.A. Amelioration of genetic hypertension by suppression of renal G protein-coupled receptor kinase type 4 expression. Hypertension 2006; 47(-6-):1131-1139. >>> Oligodeoxynucleotide, phosphorothioate antisense; oligodeoxynucleotide, missense; Ringer's solution, lactated; Kidney; Rat; 2001; 2004; 5 weeks; Controls received mp w/ vehicle, or missense oligos; tissue perfusion (kidney); pumps replaced after 1 week of vehicle; no stress (see pg. 1135); antisense (GRK4); cardiovascular; animal info (male, Wistar-Kyoto, SHR, 4 wk. old).

P7503 Shearman,L.P., Wang,S.P., Helmling,S., Stribling,D.S., Mazur,P., Ge,L., Wang,L.Y., Klussmann,S., MacIntyre,D.E., Howard,A.D., Strack,A.M. Ghrelin neutralization by a ribonucleic acid-SPM ameliorates obesity in diet-induced obese mice. Endocrinology 2006; 147(-3-):1517-1526. >>> Antisense, NOX-B11-2; RNA, spiegelmer L-; MT-II; PBS; SC; Mice; 2002; 7, 14 days; Controls received mp w/ vehicle or control SPM RNA; replacement therapy (diet-induced obesity); half-life (p.1525) 10-14 hours; animal info (male, C57BL/6N, 47 g, ghrelin -/-, WT, 41 g); synthetic RNA spiegelmer (SPM) oli.

P7852 Shimizu,H., Nakagami,H., Tsukamoto,I., Morita,S., Kunugiza,Y., Tomita,T., Yoshikawa,H., Kaneda,Y., Ogihara,T., Morishita,R. NF kappa B decoy oligodeoxynucleotides ameliorates osteoporosis through inhibition of activation and differentiation of osteoclasts. Gene Therapy 2006; 13(-12-):933-941. >>> Oligodeoxynucleotide, antisense; oligodeoxynucleotide, missense; oligodeoxynucleotide, FITC-, antisense; Rat; 2004; 2, 4 weeks; Controls received mp w/ missense ODN; functionality of mp verified by FITC-ODN fluorescence detection in tibia; antisense (NFkB); animal info (female, Wistar, 10 wk. old; male, Wistar-ODS, 8 wk. old).

P9501 Smith,R.A. Antisense oligonucleotide therapy for neurodegenerative disease. Journal of Clinical Investigation 2006; 116(-8-):2290-2296. >>> Oligonucleotide, phosphorothioate antisense; oligonucleotide, phosphorothioate missense; Saline; CSF/CNS; Rat; Rat (transgenic); 14, 28 days; Controls received mp w/ missene oligo; antisense (SOD1); brain tissue distribution; animal info (Sprague Dawley, SOD1G93A Tg, 65-75 days old); neurodegenerative (ALS).

P7746 Soucy,N.V., Riley,J.P., Templin,M.V., Geary,R., de Peyster,A., Levin,A.A. Maternal and fetal distribution of a phosphorothioate oligonucleotide in rats after intravenous infusion. BIRTH DEFECTS RESEARCH PART B-DEVELOPMENTAL AND REPRODUCTIVE TOXICOLOGY 2006; 77(-1-):22-28. >>> Oligodeoxynucleotide, phosphorothioate antisense; PBS; IV (jugular); Rat (pregnant); 2ML1; 7 days; Comparison of 3 hr. IV infusion vs. mp; no stress (see pg. 23); half-life (p. 25) 60 min.; antisense HPV; animal info (female, Sprague-Dawley, 318g, GD12-GD19); mp primed 6 hr. in sterile saline.

P7211 Butler,M., Hayes,C.S., Chappell,A., Murray,S.F., Yaksh,T.L., Hua,X.Y. Spinal distribution and metabolism of 2PRIME-O- (2-methoxyethyl)-modified oligonucleotides after intrathecal administration in rats. Neuroscience 2005; 131(-3-):705-715. >>> Oligodeoxynucleotide, phosphoro and hioate antisense; oligodeoxynucleotide, missense; Saline; CSF/CNS (intrathecal, lumbar); Rat; 2001; 3, 7 days; Controls received mp w/ missense oligos; comarison of IT bolus injections vs. mp; half-life (p. 712) "of the order of weeks"; antisense (protein kiase C alpha isozyme); "slow infusion is more efficacious than bolus dosing" (p. 712).

P7385 Ch'ang,H.J., Maj,J.G., Paris,F., Xing,H.R., Zhang,J.J., Truman,J.P., Cardon-Cardo,C., Haimovitz-Friedman,A., Kolesnick,R., Fuks,Z. ATM regulates target switching to escalating doses of radiation in the intestines. Nature Medicine 2005; 11(-5-):484-490. >>> Oligonucleotide, antisense; Saline; Mice (knockout); 7 days; Controls received mp w/ vehicle; antisense (ATM); animal info (C57BL/6, knockout, male, 8-12 weeks old).

P6950 Chen,W.H., Langer,R.M., Janczewska,S., Furian,L., Geary,R., Qu,X.M., Wang,M., Verani,R., Condon,T., Stecker,K., Bennett,C.F., Stepkowski,S.M. Methoxyethyl-modified intercellular adhesion molecule-1 antisense phosphorothiateoligonucleotides inhibit allograft rejection, ischemic-reperfusion injury, and cyclosporine-induced nephrotoxicity. Transplantation 2005; 79(-4-):401-408. >>> Oligonucleotide, antisense; Saline; IV; Rat; 7 days; Comparison of gavage and IV injections vs. mp; antisense (phosphorothioate/phosphodiester); transplantation; 14 d pump used; immunology.

P7453 Domercq,M., Etxebarria,E., Perez-Samartin,A., Matute,C. Excitotoxic oligodendrocyte death and axonal damage induced by glutamate transporter inhibition. Glia 2005; 52(-1-):36-46. >>> Oligonucleotide, antisense; oligonucleotide sense; kainate, dihydro-; aspartic acid, DL-threo-B-benzyloxy-; Saline, sterile; CSF/CNS (optic nerve); Rabbit; 1003D; 3 days; Controls received mp w/ vehicle, or contralateral nerves; antisense (glutamate transporters GLAST + GLT-1); animal info (adult, male, white New Zealand).

P7267 Fluiter,K., Frieden,M., Vreijling,J., Rosenbohm,C., de Wissel,M.B., Christensen,S.M., Koch,T., Orum,H., Baas,F. On the in vitro and in vivo properties of four locked nucleic acid nucleotides incorporated into an anti-H-Ras antisense oligonucleotide. CHEMBIOCHEM 2005; 6(-6-):1104-1109. >>> Oligodeoxynucleotide, antisense; oligodeoxynucleotide, amino-LNA antisense; oligodeoxynucleotide, thio-LNA antisense; oligodeoxynucleotide, LNA antisense; oligodeoxynucleotide, missense; SC; Mice (nude); 1002; 11 days; 48 hours; Controls received mp w/ saline; dose-response (fig. 4); no stress (see pg. 1106); stability verified by incubation in human serum; antisense (H-Ras); cancer (prostate).

P7672 Gorin,Y., Block,K., Hernandez,J., Bhandari,B., Wagner,B., Barnes,J.L., Abboud,H.E. Nox4 NAD(P) H oxidase mediates hypertrophy and fibronectin expression in the diabetic kidney. Journal of Biological Chemistry 2005; 280(-47-):39616-39626. >>> Oligonucleotide, phosphorothioate antisense; oligonucleotide, phosphorothioate sense; SC; Rat; 2 weeks; Controls received mp w/ sense oligo or not treatment; functionality of mp verified by Nox4 levels in kidney cortex; replacement therapy (STZ-induced diabetes); anti-sense (Nox4); animal info (male, Sprague-Dawley, 200-225 g).

P7723 Hofacker,A., Coste,O., Van Nguyen,H., Marian,C., Scholich,K., Geisslinger,G. Downregulation of cytosolic prostaglandin E2 synthase results in decreased nociceptive behavior in rats. Journal of Neuroscience 2005; 25(-39-):9005-9009. >>> Oligodeoxynucleotide, antisense; oligodeoxynucleotide, sense; CSF, artificial; CSF/CNS (intrathecal); Rat; 7 days; Controls received mp w/ sense ODN; antisense (cPGES); animal info (male, Sprague-Dawley); mp primed 15-18 hours in 37 Celsius saline; cPGES is cystolic Prostaglandin E2 synthases.

P7366 Kitaichi,K., Fukuda,M., Nakayama,H., Aoyama,N., Ito,Y., Fujimoto,Y., Takagi,K., Takagi,K., Hasegawa,T. Behavioral changes following antisense oligonucleotide-induced reduction of organic cation transporter-3 in mice. Neuroscience Letters 2005; 382(-1-2-):195-200. >>> Oligonucleotide, antisense; oligonucleotide, antisense, scrambled; CSF/CNS (third ventricle); Mice; 1002; 7 days; Antisense (OCT3); "The dose and infusion period of AS&SERAS used in this study did not produce any abnormal behavior or weight loss." p. 196.

P7244 Obata,K., Katsura,H., Mizushima,T., Yamanaka,H., Kobayashi,K., Dai,Y., Fukuoka,T., Tokunaga,A., Tominaga,M., Noguchi,K. TRPA1 induced in sensory neurons contributes to cold hyperalgesia after inflammation and nerve injury. Journal of Clinical Investigation 2005; 115(-9-):2393-2401. >>> SB203580; antibody, anti-nerve growth factor; oligodeoxynucleotide, antisense; oligodeoxynucleotide, FITC antisense; oligodeoxynucleotide, missense; DMSO; saline; CSF/CNS (intrathecal); Rat; 2001; 7 days; Controls received mp w/ vehicle, or sham surgery or mismatch ODN or contralateral no treatment; antisense (TRPA1); brain tissue distribution; 50% DMSO.

P7948 Porritt,M.J., Batchelor,P.E., Howells,D.W. Inhibiting BDNF expression by antisense oligonucleotide infusion causes loss of nigral dopaminergic neurons. Experimental Neurology 2005; 192(-1-):226-234. >>> Oligonucleotide, sense; oligonucleotide, reverse; oligonucleotide, antisense; oligonucleotide, antisense g-33p; PBS; CSF/CNS (substantia nigra pars compacta); Rat; 2004; 3,10,28 days; Controls received mp w/ vehicle; no stress (see pg. 228); antisense (BDNF); brain tissue distribution; cyanoacrylate adhesive; neurodegenerative (Parkinson's disease); animal info (male, Sprague-Dawley, 210-280 grams, 6-7 weeks old); unprotected oligos, rather than phosphothioate modified oligos, were used to minimize non-specific inflammatory response neurotoxicity; "infusing antisense, sense, or reverse oligonucleotides...did not affect the daily life of the animals. All were able to feed, drink, and move freely around their enclosure." (p. 228).

P7419 Schmidtko,A., Del Turco,D., Coste,O., Ehnert,C., Niederberger,E., Ruth,P., Deller,T., Geisslinger,G., Tegeder,I. Essential role of the synaptic vesicle protein synapsin II in formalin- induced hyperalgesia and glutamate release in the spinal cord. Pain 2005; 115(-1-2-):171-181. >>> Oligonucleotide, antisense; oligonucleotide, sense; CSF, artificial; CSF/CNS (intrathecal, lumbar); Rat; 2001; 6 days; Controls received mp w/ vehicle; antisense (synapsin II); animal info (male, sprague dawley); PE catheter with an O.D of 0.61 mm, 5-7 cm; pump implanted SC in tail region.

P7502 Senn,C., Hangartner,C., Moes,S., Guerini,D., Hofbauer,K.G. Central administration of small interfering RNAs in rats: A comparison with antisense oligonucleotides. European Journal of Pharmacology 2005; 522(-1-3-):30-37. >>> Oligonucleotide, phosphothioate antisense; oligonucleotide, mismatch; PBS; CSF/CNS; Rat; 2001; 7 days; Controls received mp w/ vehicle, or mismatch oligo; comparison of icv injections vs. mp; antisense (melanocortin MC4 receptor); animal info (male, Sprague-Dawley, 200 g).

P7736 Shiote,M., Nagano,I., Ilieva,H., Murakami,T., Narai,H., Ohta,Y., Nagata,T., Shoji,M., Abe,K. Reduction of a vascular endothelial growth factor receptor, fetal liver kinase-1, by antisense oligonucleotides induces motor neuron death in rat spinal cord exposed to hypoxia. Neuroscience 2005; 132(-1-):175-182. >>> Oligodeoxynucleotide, antisense; oligodeoxynucleotide, sense; oligodeoxynucleotide, missense; CSF, artificial; CSF/CNS (intrathecal, subarachnoid space); Rat; 2002; 14 days; Controls received mp w/ vehicle, or sense or missense ODN; antisense (FLK-1); animal info (adult, male, Sprague-Dawley, 8wk. old, 260-280g.).

P7524 Trevaskis,J., Walder,K., Foletta,V., Kerr-Bayles,L., McMillan,J., Cooper,A., Lee,S., Bolton,K., Prior,M., Fahey,R., Whitecross,K., Morton,G.J., Schwartz,M.W., Collier,G.R. Src homology 3-domain growth factor receptor-bound 2-like (endophilin) interacting protein 1, a novel neuronal protein that regulates energy balance. Endocrinology 2005; 146(-9-):3757-3764. >>> Oligonucleotide, antisense phosphorothioate, 2' 0me-; oligonucleotide, missense phosphorothioate, 2' 0me-; Saline; CSF/CNS; Rat; 2001; 4 days; Controls received mp w/ vehicle or missense oligo; antisense (SGIP1); animal info (male, Sprague-Dawley, 350-410 g, 16 wk old, obese).

P7392 Yamada,M., Katsuma,S., Adachi,T., Hirasawa,A., Shiojima,S., Kadowaki,T., Okuno,Y., Koshimizu,T.A., Fujii,S., Sekiya,Y., Miyamoto,Y., Tamura,M., Yumura,W., Nihei,H., Kobayashi,M., Tsujimoto,G. Inhibition of protein kinase CK2 prevents the progression of glomerulonephritis. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 2005; 102(-21-):7736-7741. >>> Oligodeoxynucleotide, antisense; Kidney (renal cortex); Rat; 1002; 14 days; Urinalysis; antisense (CK2alpha); animal info (male, Wistar-Kyoto, 300-350 g and female, Wistar-Kyoto, 120-140 g); pump implanted in the IP cavity.

P6646 Aharinejad,S., Paulus,P., Sioud,M., Hofmann,M., Zins,K., Schaefer,R., Stanley,E.R., Abraham,D., Aharinejad,S. Colony-stimulating factor-1 blockade by antisense oligonucleotides and small interfering RNAs suppresses growth of human mammary tumor xenografts in mice. Cancer Research 2004; 64(--):5378-5384. >>> Oligonucleotide, antisense; oligonucleotide, scrambled; Ringer's solution; SC; Mice (nude); 1002; 14 days; Controls received mp w/ vehicle; antisense (CSF)-1; cancer (carcinoma, breast); transplantation.

P7121 Beaudry,G., Zekki,H., Rouillard,C., Levesque,D. Clozapine and dopamine D3 receptor antisense reduce cocaine-and amphetamine-regulated transcript expression in the rat nucleus accumbens shell. Synapse 2004; 51(-4-):233-240. >>> Oligodeoxynucleotide, phosphorothioate antisense; oligodeoxynucleotide, missense; CSF, artificial; CSF/CNS; Rat; 2001; 5 days; Controls received mp w/vehicle, or missense ODN; antisense (dopamine receptors D2, D3); ALZET brain infusion kit 2 used; post op. care (ampicillin).

P6270 Blakley,G.G., Pohorecky,L.A., Benjamin,D. Behavioral and endocrine changes following antisense oligonucleotide-induced reduction in the rat NOP receptor. Psychopharmacology 2004; 171(-4-):421-428. >>> Oligonucleotide, antisense; oligonucleotide, missense; Water, nuclease free; CSF/CNS; Rat; 2004; 26 days; Controls received mp w/ MSO; antisense (NOP receptor); multiple pumps per animal (2); bilateral infusion using plastics one cannula.

P6647 Caille,I., Allinquant,B., Dupont,E., Bouillot,C., Langer,A., Mueller,U., Prochiantz,A. Soluble form of amyloid precursor protein regulates proliferation of progenitors in the adult subventricular zone. Development 2004; 131(-9-):2173-2181. >>> Amyloid precursor protein-Fc, soluble; batimastat; immunoglobulin G, human; amyloid precursor like protein 2-Fc, soluble; oligonucleotide, antisense penetratin; Ara-C; Sodium chloride; saline; CSF/CNS; Mice; 1003D; 1007D; 3,6 days; Controls received mp w/ vehicle; antisense (APP, APLP2); brain tissue distribution; batimastat inhibits clearage of several membrane proteins; neurodegenerative disease (Alzheimer's).

P5995 Dorn,G., Patel,S., Wotherspoon,G., Hemmings-Mieszczak,M., Barclay,J., Natt,F.J.C., Martin,P., Bevan,S., Fox,A., Ganju,P., Wishart,W., Hall,J. siRNA relieves chronic neuropathic pain. NUCLEIC ACIDS RESEARCH 2004; 32(-5-):1-6. >>> RNA, small interfering; oligonucleotide, antisense; Saline; CSF/CNS (intrathecal); Rat; 6-7 days; Controls received mp w/ missense siRNA; no stress (see pg. 4); antisense (P2X3); gene therapy; siRNA (P2X3); pain research.

P6625 Hernandez,A., Constandil,L., Laurido,C., Pelissier,T., Marchand,F., Ardid,D., Alloui,A., Eschalier,A., Soto-Moyano,R. Venlafaxine-induced depression of wind-up activity in mononeuropathic rats is potentiated by inhibition of brain 5-HT1A receptor expression in vivo. International Journal of Neuroscience 2004; 114(-2-):229-242. >>> Oligodeoxynucleotide, antisense; oligodeoxynucleotide, scrambled; Saline; CSF/CNS; Rat; 2004; 7 days; Controls received mp w/ vehicle; antisense (5-HT1A) receptor; incorrectly states the 2004 pumping rate as 2.5 ul/hr; cannula secured by dental cement.

P7081 Matsuno,A., Katayama,H., Murakami,M., Nagashima,T. In vivo growth suppression of rat C6 glioma transplanted in rat brain using antisense oligonucleotide for microtubule-associated protein 1A messenger ribonucleic acid. British Journal of Neurosurgery 2004; 18(-4-):343-346. >>> Oligodeoxynucleotide, phosphorothisate antisense; oligodeoxynucleotide, phosphorothisate sense; oligodeoxynucleotide, phosphorothisate scramble; Saline, sterile; CSF/CNS (intratumoral); Rat; 1007D; 1 week; Controls received mp w/ sense or scrambled oligos; antisense (microtubule-associated protein 1A); cancer (glioma).

R0208 Shoji,Y., Nakashima,H. Current status of delivery systems to improve target efficacy of oligonucleotides. CURRENT PHARMACEUTICAL DESIGN 2004; 10(-7-):785-796. >>> Oligonucleotide, antisense; SC; intratumoral; ; Cancer (adenocarcinoma); surgical sutures used to immobilize the pumps.

P6265 Tepel,J., Kruse,M.L., March,C., Fiedler,A., Kapischke,M., Ketterer,T., Sipos,B., Kremer,B., Kalthoff,H. Terminally modified oligodeoxynucleotides directed against p53 in an orthotopic xenograft model: A novel adjuvant treatment strategy for pancreatic ductal carcinoma. Pancreas 2004; 28(-1-):1-12. >>> Oligodeoxynucleotide, antisense; SC; Mice (SCID); 14 days; Tissue perfusion (intratumoral); comparison of IP injections vs. sc mp; cancer (pancreatic ductal carcinoma); transplantation; 200 ul pump used.

P7073 Thallinger,C., Wolschek,M.F., Maierhofer,H., Skvara,H., Pehamberger,H., Monia,B.P., Jansen,B., Wacheck,V., Selzer,E. Mcl-1 is a novel therapeutic target for human sarcoma: synergistic inhibition of human sarcoma xenotransplants by a combination of Mcl-1 antisense Oligonucleotides with low-dose cyclophosphamide. Clinical Cancer Research 2004; 10(-12-):4185-4191. >>> Oligodeoxynucleotide, phosphorothisate antisense; oligonucleotide, universal control; Saline; SC; Mice (SCID); 2002; 2 weeks; Controls received mp w/ vehicle, or UC oligo; antisense (Mcl-1); cancer (liposarcoma).

P6264 Vemuganti,R., Dempsey,R.J., Bowen,K.K. Inhibition of intercellular adhesion molecule-1 protein expression by antisense oligonucleotides is neuroprotective after transient middle cerebral artery occlusion in rat. Stroke 2004; 35(-1-):179-184. >>> Oligonucleotide, antisense; CSF, artificial; CSF/CNS; Rat; 2001; 1 day; Controls received mp w/ vehicle; cardiovascular.

P7107 Wagner,W., Fogel,W.A. Mammary histidine decarboxylase vulnerability to enzyme antisense oligonucleotides: Histamine and polyamine systems cross-talk. Amino Acids 2004; 26(--):311-316. >>> Oligodeoxynucleotide, phosphorothioate antisense; oligodeoxynucleotide, sense; Saline, sterile; SC; Mice; 1007D; 1 week; Controls received no treatment; antisense (histidine decarboxylase).

P6132 Burkhart,C.A., Cheng,A.J., Madafiglio,J., Kavallaris,M., Mili,M., Marshall,G.M., Weiss,W.A., Khachigian,L.M., Norris,M.D., Haber,M. Effects of MYCN antisense oligonucleotide administration on tumorigenesis in a murine model of neuroblastoma. Journal of the National Cancer Institute 2003; 95(-18-):1394-1403. >>> Oligonucleotide, antisense; SC; Mice (transgenic); 2002; 6 weeks; Antisense (MYCN); cancer (neuroblastoma).

P5726 Eder,I.E, Hoffmann,J, Rogatsch,H, Schafer,G, Zopf,D, Bartsch,G, Klocker,H  Cancer Gene Therapy 2003; 9(-2-):117-125. >>> Oligonucleotide, antisense; Water, distilled; SC; Mice (nude); 7 weeks; Controls received mp w/ vehicle; long-term study, pumps replaced every two weeks; no stress (see pg. 122); cancer (prostate); antisense; pumps implanted SC in the vicinity of tumors; ODN w/ specificity to the androgen receptor; "...mice did not show any reaction on the subcutaneously installed ALZET diffusion pumps. These were chosen to guarantee a continuous systemic administration of oligonucleotides, a commonly used method for antisense treatment in vivo." (p 122).

P5603 Fluiter,K., ten Asbroek,A.L.M.A., de Wissel,M.B., Jakobs,M.E., Wissenbach,M., Olsson,H., Olsen,O., Oerum,H., Baas,F. In vivo tumor growth inhibition and biodistribution studies of locked nucleic acid (LNA) antisense oligonucleotides. NUCLEIC ACIDS RESEARCH 2003; 31(-3-):953-962. >>> Oligonucleotide, antisense; Saline; SC; Mice (nude); 1002; 14 days; Controls received mp/ w vehicle; dose response (graph p. 959); half-life (p. 956); cancer; peptides; antisense; LNA PO ODN's used.

P5998 Hsu,F.C., Smith,S.S. Progesterone withdrawal reduces paired-pulse inhibition in rat hippocampus: Dependence on GABA(A) receptor alpha 4 subunit upregulation. Journal of Neurophysiology 2003; 89(-1-):186-198. >>> Oligonucleotide, phosphorotioate antisense; BSA; Saline; CSF/CNS; Rat; 1003D; 72 hours; Controls received mp w/ missense oligos; antisense (GABA receptor a4 subunit); dependence.

P6542 Isogawa,K., Akiyoshi,J., Tsutsumi,T., Kodama,K., Horinouti,Y., Nagayama,H. Anxiogenic-like effect of corticotropin-releasing factor receptor 2 antisense oligonucleotides infused into rat brain. JOURNAL OF PSYCHOPHARMACOLOGY 2003; 17(-4-):409-413. >>> Oligonucleotide, antisense; oligonucleotide, scrambled; CSF/CNS; Rat; 1003D; 1007D; ; Antisense (CRF-R2); ALZET brain infusion kit 1 used; post op. care (IP injection of ceftriaxone sodium to minimize infection); behavioral testing.

P6601 McMahon,B.M., Stewart,J., Fauq,A., Younkin,S., Younkin,L., Richelson,E. Peptide nucleic acids targeted to the amyloid precursor protein. Journal of Molecular Neuroscience 2003; 20(-3-):261-265. >>> Peptide nucleic acid, antisense; peptide nucleic acid, missense; CSF/CNS; Mice; 2004; 28 days; Controls received mp w/ saline; comparison of ICV injections vs. mp; antisense (beta-site APP-clearing enzyme) (BACE); neurodegenerative disease (Alzheimer's).

P6194 Mizuno,M., Yamada,K., Takei,N., Tran,M.H., He,J., Nakajima,A., Nawa,H., Nabeshima,T. Phosphatidylinositol 3-kinase: a molecule mediating BDNF-dependent spatial memory formation. Molecular Psychiatry 2003; 8(-2-):217-224. >>> Oligonucleotide, antisense; oligonucleotide, sense; wortmannin; Saline, pyrogen-free; DMSO; CSF/CNS; Rat; 2004; 1 week; 25 days; Enzyme inhibitor (phosphatidylinositol 3-kinase); sense and antisense (BDNF).

P5600 Sun,Y.J., Jin,K.L., Peel,A., Mao,X.O., Xie,L., Greenberg,D.A. Neuroglobin protects the brain from experimental stroke in vivo. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 2003; 100(-6-):3497-3500. >>> Oligodeoxynucleotide, antisense; oligodeoxynucleotide, sense; CSF, artificial; CSF/CNS; Rat; 1003D; 72 Hours; Antisense (neuroglobin); ischemia (cerebral).

P6619 Suzukawa,J., Omori,K., Yang,L., Inagaki,C. Continuous administration of antisense oligonucleotides to c-fos reduced the development of seizure susceptibility after ethacrynic acid-induced seizure in mice. Neuroscience Letters 2003; 349(-1-):21-24. >>> Oligodeoxynucleotide, phosphorothioate antisense; oligodexynucleotide, phosphorothioate sense; HEPES buffer; sodium chloride; CSF/CNS; Mice; 2002; 9 days; Controls received mp w/ sense ODN; antisense (C-fos); ALZET brain infusion kit used; after experiment, the settled position of the cannula was confirmed.

P5609 Van Kampen,J.M., Stoessl,A.J. Effects of oligonucleotide antisense to dopamine D-3 receptor mRNA in a rodent model of behavioural sensitization to levodopa. Neuroscience 2003; 116(-1-):307-314. >>> Oligonucleotide, antisense; oligonucleotide, missense; Saline; CSF/CNS (striatum); Rat; 2001; ; Controls received mp w/ vehicle; antisense; neurodegenerative (Parkinson's disease); nonspecific toxicity of antisense administration was minimized by "the use of partial rather than complete phosphorothioate modification, reducing the length of the oligonucleotide, and using a steady continuous infusion rather than bolus injections...(p. 309)..

P5601 Van Oekelen,D., Megens,A., Meert,T., Luyten,W.H.M.L., Leysen,J.E. Functional study of rat 5-HT2A receptors using antisense oligonucleotides. Journal of Neurochemistry 2003; 85(-5-):1087-1100. >>> Oligonucleotide, antisense; Oligonucleotide, sense; Saline; CSF/CNS; Rat; 2001; 1-6 days; Controls received mp w/ vehicle; ALZET brain infusion kit used; brain tissue distribution; antisense; cannula placement and ODN distribution were examined by 60 hour infusion of evans blue or thio ATP-labeled ODN; oligonucleotides had specificity to serotonin receptor mRNA.

P5505 Aharinejad,S., Abraham,D., Paulus,P., Abri,H., Hofmann,M., Grossschmidt,K., Schafer,R., Stanley,E.R., Hofbauer,R. Colony-stimulating factor-1 antisense treatment suppresses growth of human tumor xenografts in mice. Cancer Research 2002; 62(-18-):5317-5324. >>> Oligonucleotide, sense; oligonucleotide, antisense; SC; Mice (scid); mice (nude); 1002; 14 days; Controls received mp w/ Ringer's; cancer; antisense.

P6310 Barclay,J., Patel,S., Dorn,G., Wotherspoon,G., Moffatt,S., Eunson,L., Abdel'al,S., Natt,F., Hall,J., Winter,J., Bevan,S., Wishart,W., Fox,A., Ganju,P. Functional Downregulation of P2X3 Receptor Subunit in Rat Sensory Neurons Reveals a Significant Role in Chronic Neuropathic and Inflammatory Pain. The Journal of Neuroscience 2002; 22(-18-):8139-8147. >>> Oligonucleotide, antisense; oligonucleotide, missense; CSF/CNS (intrathecal); Rat; 2001; 7 days; Controls received mp w/ saline; functionality of mp verified by fluorescently labeled antisense oligonucleotide; no stress (see pg. 8140, 8144); antisense (P2X3 receptor); post op. care (antibiotic powder); P2X is an ATP-gated cation channel.

P5117 Boye,S.M., Pradhan,A.A.A., Grant,R.J., Clarke,P.B.S. Evidence for sequence-dependent and reversible nonspecific effects of PS-capped antisense treatment after intracerebral administration. Antisense&Nucleic Acid Drug Development 2002; 12(--):95-102. >>> Oligodeoxynucleotide, antisense; Saline; CSF/CNS (ventral tegmental area); rat; 2002; 2 weeks; Controls received mp w/ vehicle; antisense; phosphorothioate phosphodiester, or mismatch oligonucleotides used.

P5550 Cenci,M.A. Transcription factors involved in the pathogenesis of L-DOPA-induced dyskinesia in a rat model of Parkinson's disease. Amino Acids 2002; 23(-1-3-):105-109. >>> Oligonucleotide, antisense; CSF/CNS (striatum); Rat; 14 days; Neurodegenerative (Parkinson's disease); Antisense oligo is to cyclic AMP response - element binding protein (CREB).

P5049 Elepfandt,P., Rupprecht,S., Schoning-Burkhardt,B., Volk,H.D., Woiciechowsky,C. Oligodeoxynucleotides induce brain inflammation in rats when infused intracerebroventricularly. Neurosci.Lett. 2002/4/5; 322(--):107-110. >>> Oligodeoxynucleotide, antisense; Saline; Albumin, human serum; CSF/CNS; rat; 1003D; 48 hours; controls received mp w/ vehicle; immunology; brain inflammation due to ICV nucleotide.

P5584 Falk,E.M., Cook,V.J., Nichols,D.E., Sprague,J.E. An antisense oligonucleotide targeted at MAO-B attenuates rat striatal serotonergic neurotoxicity induced by MDMA. Pharmacol Biochem.Behav. 2002; 72(--):617-622. >>> Oligodeoxynucleotide, antisense; CSF/CNS; rat; 1007D; 7 days; antisense; "Utilizing continuous minipump administration enhances the knockdown to 63% of control." (p. 619) This compared with 40% by twice daily administration. "The results of the present study confirm the utility of osmotic minipump administration of antisense oligonucleotides." (p. 621).

P5278 Fluiter,K., ten Asbroek,A.L., van Groenigen,M., Nooij,M., Aalders,M.C., Baas,F. Tumor genotype-specific growth inhibition in vivo by antisense oligonucleotides against a polymorphic site of the large subunit of human RNA polymerase II. Cancer Res 2002/4/1; 62(-7-):2024-2028. >>> Oligodeoxynucleotide, antisense; Saline; SC; Mice (nude); 1002; 48 hrs, 8 days, 14 days; Controls received mp w/ vehicle; cancer; phosphorothioate sense and antisense used.

P5578 Fundytus,M.E., Osborne,M.G., Henry,J.L., Coderre,T.J., Dray,A. Antisense oligonucleotide knockdown of mGluR(1) alleviates hyperalgesia and allodynia associated with chronic inflammation. Pharmacology Biochemistry and Behavior 2002; 73(-2-):401-410. >>> Oligonucleotide, antisense; CSF, artificial; CSF/CNS (intrathecal, lumbar); rat; 2001; 7 days; controls received mp with missense oligonucleotide or vehicle; antisense; lumbar approach chosen to minimize trauma from catheter insertion, which the authors felt allowed for pump implantation during the same surgery.

P5487 Honore,P., Kage,K., Mikusa,J., Watt,A.T., Johnston,J.F., Wyatt,J.R., Faltynek,C.R., Jarvis,M.F., Lynch,K. Analgesic profile of intrathecal P2X3 antisense oligonucleotide treatment in chronic inflammatory and neuropathic pain states in rats. Pain 2002; 99(-1-2-):11-19. >>> Oligonucleotide, antisense; Water, sterile; CSF/CNS (intrathecal); Rat; 2001; 7 days; Comparison of single bolus injections vs mp.

P5080 Hou,J.W., Li,B., Yang,Z.H., Fager,N., Ma,M.Y.J. Functional integrity of ErbB-4/-2 tyrosine kinase receptor complex in the hypothalamus is required for maintaining normal reproduction in young adult female rats. Endocrinology 2002; 143(-5-):1901-1912. >>> Oligodeoxynucleotide, antisense; oligodeoxynucleotide, scrambled; CSF, artificial; CSF/CNS (preoptic area); CSF/CNS (hypothalamus); rat; 2002; 14 days; controls received scrambled oligodeoxynucleotide; functionality of mp verified by residual aspiration; antisense or scrambled ODN coded for estrogen receptor B2 gene activity; cannula patency verified at termination.

P5389 Kagiyama,S., Eguchi,S., Frank,G.D., Inagami,T., Zhang,Y.C., Phillips,M.I. Angiotensin II-induced cardiac hypertrophy and hypertension are attenuated by epidermal growth factor receptor antisense. Circulation 2002; 106(-8-):909-912. >>> Angiotensin II; Oligodeoxynucleotide, antisense; SC; IV; Rat; 2002; 2ML4; 14 days; Antisense; multiple pumps per animal (2); 2002 pump implanted SC for Ang II delivery and 2ML2 used for IV administration of antisense.

P5387 Kanthasamy,A., Sprague,J.E., Shotwell,J.R., Nichols,D.E. Unilateral infusion of a dopamine transporter antisense into the substantia nigra protects against MDMA-induced serotonergic deficits in the ipsilateral striatum. Neuroscience 2002; 114(-4-):917-924. >>> Oligodeoxynucleotide, antisense; oligodeoxynucleotide, missense; CSF, artificial; CSF/CNS (substantia nigra); Rat; 1007D; 7 days; Antisense; topical antibiotic used on incision to prevent infection; cannula placement verified post-experimentally by melthylene blue dye injection; antisense with specificity to dopamine transporter were used.

P5377 Liang,Y.Q., Akishita,M., Kim,S., Ako,J., Hashimoto,M., Iijima,K., Ohike,Y., Watanabe,T., Sudoh,N., Toba,K., Yoshizumi,M., Ouchi,Y. Estrogen receptor beta is involved in the anorectic action of estrogen. International Journal of Obesity 2002; 26(-8-):1103-1109. >>> Estradiol, 17B-; Oligonucleotide, antisense; Cyclodextrin, 2-hydroxypropyl-beta (molecusol)-; fluorescein isothiocyanate; CSF/CNS; Rat; 2002; 3 weeks; Replacement therapy (ovariectomy); pumps replaced after one week; ALZET brain infusion kit used; initial pump delivered saline only for one week to allow for surgical recovery prior to 2 weeks of hormone administration.

P6165 Morrissey,D.V., Lee,P.A., Johnson,D.A., Overly,S.L., McSwiggen,J.A., Beigelman,L., Mokler,V.R., Maloney,L., Vargeese,C., Bowman,K., O'Brien,J.T., Shaffer,C.S., Conrad,A., Schmid,P., Morrey,J.D., Macejak,D.G., Pavco,P.A., Blatt,L.M. Characterization of nuclease-resistant ribozymes directed against hepa titis B virus RNA. JOURNAL OF VIRAL HEPATITIS 2002; 9(-6-):411-418. >>> Ribozyme; oligonucleotide, antisense; Saline; SC; Mice (transgenic); 14 days; Controls received mp w/ vehicle; antisense.

P5963 Murata,M., Suzuki,M., Tanaka,K., Tajiri,K., Emori,K., Kurachi,M. N-methyl-D-aspartate-R1 receptor antisense oligodeoxynucleotide modula tes pre- and postsynaptic expression of D-2 dopamine receptors in the rat. Neuroscience Letters 2002; 335(-1-):9-12. >>> Oligodeoxynucleotide, antisense; oligodeoxynucleotide, sense; Saline, sterile; CSF/CNS; Rat; 2001; 7 days; Controls received mp w/ vehicle; antisense (nmda receptors).

P5825 Obici,S., Zhang,B.B., Karkanias,G., Rossetti,L. Hypothalamic insulin signaling is required for inhibition of glucose production. Nature Medicine 2002; 8(-12-):1376-1382. >>> Oligodeoxynucleotide, antisense; CSF, artificial; CSF/CNS; Rat; 2001; 3-7 days; Controls received mp w/ vehicle; antisense (suppressor of cytokine signaling-3); cardiovascular; ALZET brain infusion kit used; brain tissue distribution; cerebral ischemia; "A good distribution of the FITC conjugated antisense was seen around the lateral ventricles, septum, striatum, hippocampus and cortex bilaterally." (p. 1075); ischemia (cerebral); MCAO.

P5472 Sharif,R.N., Osborne,M., Coderre,T.J., Fundytus,M.E. Attenuation of morphine tolerance after antisense oligonucleotide knock-down of spinal mGluR1. British Journal of Pharmacology 2002; 136(-6-):865-872. >>> Oligonucleotide, antisense; oligonucleotide, missense; CSF, artificial; CSF/CNS (intrathecal); Rat; 2001; 7 days; Controls received mp w/ vehicle; tolerance; antisense; oligonuceltides had specificity to metabotropic glutamate receptor.

P5143 Torner,L., Toschi,N., Nava,G., Clapp,C., Neumann,I.D. Increased hypothalamic expression of prolactin in lactation: involvement in behavioural and neuroendocrine stress responses. European Journal of Neuroscience 2002; 15(--):1381-1389. >>> Oligodeoxynucleotide, antisense; Prolactin, ovine; Ringer's solution; CSF/CNS; Rat (lactating); 1007D; 5 days; controls received mp w/ vehicle; antisense; oligonucleotides against the long form of the brain Prolactin receptor.

P6202 Wacheck,V., Krepler,C., Strommer,S., Heere-Ress,E., Klem,R., Pehamberger,H., Eichler,H.G., Jansen,B. Antitumor effect of G3139 Bcl-2 antisense oligonucleotide is independent of its immune stimulation by CpG motifs in SCID mice. Antisense&Nucleic Acid Drug Development 2002; 12(-6-):359-367. >>> Oligonucleotide, antisense; Saline; SC; Mice (SCID); 2002; 14 days; Controls received mp w/ vehicle; comparison of ip injections vs. mp; antisense (Bcl-2); cancer (melanoma).

P5357 Walker,T.L., Dass,C.R., Burton,M.A. Enhanced In Vivo tumour response from combination of carboplatin and low-dose c-myc antisense oligonucleotides. Anticancer Research 2002; 22(-4-):2237-2245. >>> Oligonucleotide, antisense; FITC label; SC; mice; 86 hours; Cardiovascular; antisense oligonucleotide infused was a protein kinase C-alpha phosphorothioate-modified oligonucleotide.

P4886 Garver,E., Tu,G.C., Cao,Q.N., Aini,M., Zhou,F., Israel,Y. Eliciting the low-activity aldehyde dehydrogenase Asian phenotype by an antisense mechanism results in an aversion to ethanol. Journal of Experimental Medicine 2001; 194(-5-):571-580. >>> Oligonucleotide, antisense; PBS; IP; rat; 2ML1; 4 days; controls received mp w/ vehicle; functionality of mp verified by plasma acetaldehyde levels; dose reponse (table IV p. 577); antisense; ASO-9 is an antisense phosphorothioate oligonucleotide that mimics the low-activity ALDH2-2 Asian phenotype..

P4894 Ibrahim,M.M., Mata,H.P., Chawla,M., Lai,J., Porreca,F., Malan,TP Jr  JOURNAL OF PAIN 2001; 2(-4-):241-249. >>> Oligonucleotide, antisense; Oligonucleotide, mismatch; Saline; CSF/CNS (intrathecal); rat; 6 days; controls received mp w/ vehicle; functionality of mp verified by immunocytochemistry of ODN-delivered cells; antisense ODN delivered was for mRNA of c-fos, a cellular transcription factor implicated in neuronal activity surrounding nociception..

P4785 Kishioka,H., Fukuda,N., Hu,W.Y., Nakayama,M., Watanabe,Y., Kanmatsuse,K. Effects of PDGF A-chain antisense oligodeoxynucleotides on growth of cardiovascular organs in stroke-prone spontaneously hypertensive rats.. American Journal of Hypertension 2001; 14(--):439-445. >>> Oligodeoxynucleotide, antisense; Oligodeoxynucleotide, sense;; Water;; SC;; rat;; 2ML4;; 28 days;; Controls received mp w/ vehicle; cardiovascular; antihypertensive; antisense; PDGF A-chain antisense and sense nucleotides used;.

P5019 Moore,A.F., Heiderstadt,N.T., Huang,E., Howell,N.L., Wang,Z.Q., Siragy,H.M., Carey,R.M. Selective inhibition of the renal angiotensin type 2 receptor increases blood pressure in conscious rats. Hypertension 2001; 37(--):1285-1291. >>> Oligodeoxynucleotide, antisense; Oligodeoxynucleotide, sense;; Ringer's solution, lactated; Kidney (renal cortex); rat; 2001; 7 days; controls received sense ODN or vehicle w/ mp; tissue perfusion (left renal interstitial space); cardiovascular.

P5208 Ramoa,A.S., Mower,A.F., Liao,D., Jafri,S.I. Suppression of cortical NMDA receptor function prevents development of orientation selectivity in the primary visual cortex. J Neurosci. 2001/6/15; 21(-12-):4299-4309. >>> Oligodeoxynucleotide, antisense; Oligodeoxynucleotide, sense; Oligodeoxynucleotide, missense; PBS; CSF/CNS (visual cortex); Ferret; 2002; 2004; 4 weeks; Controls received mp w/ missense ODNs; pumps replaced every 2 weeks; antisense ODN suppessed NMDA receptor; infusion rate set at 0.5 ul/hr, which was achieved by multiple pumps per animal (2) 2004 pumps implanted simultaneously or 2002 pumps replaced after 2 weeks.

P4950 Rao,W.L.R., Dogan,A., Bowen,K.K., Dempsey,R.J. Ornithine decarboxylase knockdown exacerbates transient focal cerebral ischemia-induced neuronal damage in rat brain. Journal of Cerebral Blood Flow and Metabolism 2001; 21(--):945-954. >>> Oligonucleotide, antisense; Olignucleotide, sense; CSF, artificial; CSF/CNS; rat; 2001; 5 days; controls received sense ODN, aCSF vehicle; functionality of mp verified incorrectly by weighing pumps after sacrifice; antisense; ODN used was ornithine decarboxylase antisense ODN; ischemia (cerebral); MCAO.

P4954 Torner,L., Toschi,N., Pohlinger,A., Landgraf,R., Neumann,I.D. Anxiolytic and anti-stress effects of brain prolactin: Improved efficacy of antisense targeting of the prolactin receptor by molecular modeling. Journal of Neuroscience 2001; 21(-9-):3207-3214. >>> Oligonucleotide, antisense; Saline; CSF/CNS; Rat; 2002; 5 days; Controls received mp w/ vehicle; ALZET brain infusion kit used; antisense infusion was delayed for 4 days by vehicle infusion to allow recovery period from surgery; air bubble used as spacer to separate vehicle from antisense solution.

P4347 Lara,H.E., Dissen,G.A., Leyton,V., Paredes,A., Fuenzalida,H., Fiedler,J.L., Ojeda,S.R. An increased intraovarian synthesis of nerve growth factor and its low affinity receptor is a principal component of steroid-induced polycystic ovary in the rat. Endocrinology 2000; 141(-3-):1059-1072. >>> Antibody, nerve growth factor, polyclonal; Oligonucleotide, antisense phosphothionate;; Intraovarian;; rat;; 2ML4;; 56 days;; controls received mp with preimmune serum; tissue perfusion (bursa of ovary); long-term study, pumps replaced after 28 days; peptides; antisense; agents infused from same pump;.

P4683 Lin,S.-B, Wu,L.-C, Huang,S.-L, Hsu,H.-L, Hsieh,S.-H, Chi,C.-W, Au,L.-C  Journal of Hepatology 2000; 33(--):601-608. >>> Oligonucleotide, antisense;; Saline;; IP;; rat;; 2002;; 14 days;; Cancer; antisense; liver tumor cell proliferation, PKC antisense oligonucleotide used..

P6184 Neumann,I.D. Antisense oligodeoxynucleotide effects on the hypothalamic-neurohypophysial system and the hypothalamic-pituitary-adrenal axis. METHODS 2000/11; 22(-3-):227-237. >>> Oligodeoxynucleotide, antisense; Ringer's solution; CSF/CNS; Rat (lactating); 1007D; 4 days; Tissue perfusion (various brain regions); comparison of ICV injections vs. mp; pulsed delivery (various ODN's, air bubble spacer); antisense; ODN's infused were antisense, mixed base, or 21-mer end capped phosphorothioated; the mp was filled with ringer's solution and PE tubing was filled w/ 50 ul of each agent solution. An air bubble was inserted between solutions; 25-g guide cannula and 27-g infusion cannula used together to allow concomitant icv injections.